Husnu Celik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Husnu Celik has a total of 99 co-authors. Here are the top co-authors by number of shared publications:
- Gülşen Doğan Durdağ
Department of Gynecology and Obstetrics, Adana Dr. Turgut Noyan Application and Research Hospital, Başkent University Faculty of Medicine, 01250 Adana, Turkey
11 shared publications - Songül Alemdaroğlu
Başkent University
9 shared publications - Ali Ayhan
School of Medicine, Department of Obstetrics and Gynecology, Başkent University, Bahçelievler, Ankara, Turkey
8 shared publications - Seda Yüksel Şimşek
Baskent University Adana Dr. Turgut Noyan Teaching Hospital, Turkey
8 shared publications - Şafak Yılmaz Baran
Department of Obstetrics and Gynecology, Başkent University Faculty of Medicine, Adana, Turkey
7 shared publications Bilgin Gurates
Division of Gynecologic Oncology, Department of Obstetric and Gynecology, Firat University, Medicine School, Elazig, Turkey
6 shared publications
Latest Publications
- 9 June 2026
- Published by Academician Publishing
- p. 609-616
Fertilite İlaçları ve Kanser
- 28 January 2026
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 52 (2) , e70189
Impact of Power Morcellation and Histopathological Subtypes on the Development of Peritoneal Leiomyomatosis Following Laparoscopic Myomectomy
Aim: Laparoscopic myomectomy with power morcellation is a common approach for the management of uterine myomas. However, besides myoma recurrence, rare complications such as peritoneal leiomyomatosis may arise postoperatively. The histopathological subtype of fibroids—particularly cellular leiomyoma—may impact the risk of recurrence and dissemination, though current evidence remains limited. The aim of this study is to evaluate the impact of power morcellation on the development of disseminated peritoneal leiomyomatosis and to assess the association between the histopathological subtype of myoma and patient outcomes during follow‐up. Methods: This retrospective cohort study analyzed 997 patients who underwent laparoscopic myomectomy with power morcellation at a single tertiary center between 2012 and 2024. Patients were followed through clinical evaluations and ultrasonography. Peritoneal leiomyomatosis was evaluated in relation to surgical technique (confined vs. unconfined morcellation) and histopathological subtype. Results: Of the 553 patients with available follow‐up, myoma recurrence was observed in 130 (23.5%), reoperation in 53 (9.6%), and peritoneal leiomyomatosis in 8 patients (1.4%). All peritoneal leiomyomatosis cases occurred in the unconfined morcellation group. Cellular leiomyoma was identified in 5 of the 8 peritoneal leiomyomatosis cases (62.5%). One peritoneal leiomyomatosis case was diagnosed as leiomyosarcoma after surgery for disseminated leiomyomatosis. Overall myoma recurrence was significantly higher in patients with multiple myomas and in those with cellular leiomyoma. Conclusion: Peritoneal leiomyomatosis is a rare complication of laparoscopic myomectomy and increased incidence after unconfined morcellation is a serious concern. Confined (in‐bag) morcellation appears to reduce the risk of peritoneal leiomyomatosis and should be the standard of care. Diagnosis of myomas as cellular leiomyoma subtype on histopathology merits high clinical suspicion for possibility of subsequent peritoneal leiomyomatosis in patients with unconfined morcellation. Therefore, close and long‐term follow‐up of these patients is essential.
- 28 January 2026
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 52 (2) , e70189
Impact of Power Morcellation and Histopathological Subtypes on the Development of Peritoneal Leiomyomatosis Following Laparoscopic Myomectomy
Aim: Laparoscopic myomectomy with power morcellation is a common approach for the management of uterine myomas. However, besides myoma recurrence, rare complications such as peritoneal leiomyomatosis may arise postoperatively. The histopathological subtype of fibroids—particularly cellular leiomyoma—may impact the risk of recurrence and dissemination, though current evidence remains limited. The aim of this study is to evaluate the impact of power morcellation on the development of disseminated peritoneal leiomyomatosis and to assess the association between the histopathological subtype of myoma and patient outcomes during follow‐up. Methods: This retrospective cohort study analyzed 997 patients who underwent laparoscopic myomectomy with power morcellation at a single tertiary center between 2012 and 2024. Patients were followed through clinical evaluations and ultrasonography. Peritoneal leiomyomatosis was evaluated in relation to surgical technique (confined vs. unconfined morcellation) and histopathological subtype. Results: Of the 553 patients with available follow‐up, myoma recurrence was observed in 130 (23.5%), reoperation in 53 (9.6%), and peritoneal leiomyomatosis in 8 patients (1.4%). All peritoneal leiomyomatosis cases occurred in the unconfined morcellation group. Cellular leiomyoma was identified in 5 of the 8 peritoneal leiomyomatosis cases (62.5%). One peritoneal leiomyomatosis case was diagnosed as leiomyosarcoma after surgery for disseminated leiomyomatosis. Overall myoma recurrence was significantly higher in patients with multiple myomas and in those with cellular leiomyoma. Conclusion: Peritoneal leiomyomatosis is a rare complication of laparoscopic myomectomy and increased incidence after unconfined morcellation is a serious concern. Confined (in‐bag) morcellation appears to reduce the risk of peritoneal leiomyomatosis and should be the standard of care. Diagnosis of myomas as cellular leiomyoma subtype on histopathology merits high clinical suspicion for possibility of subsequent peritoneal leiomyomatosis in patients with unconfined morcellation. Therefore, close and long‐term follow‐up of these patients is essential.
- Open Access
- 19 December 2024
- Published by Mebas Medikal Basin Yayin Ltd. Sti in Gynecology Obstetrics & Reproductive Medicine
- p. 1-6
The Effects of the COVID-19 Pandemic on Abnormal Uterine Bleeding According to the PALM-COEIN Classification
OBJECTIVE: To investigate the impact of the COVID-19 pandemic on abnormal uterine bleeding (AUB) according to the PALM-COEIN classification. STUDY DESIGN: Patients who underwent surgical intervention due to AUB were categorized according to the PALM-COEIN classification, and the pandemic period was compared with the pre-pandemic period. RESULTS: During the COVID-19 pandemic, an increase in abnormal uterine bleeding (AUB) was observed. This was statistically shown to be due to ovulatory dysfunction and endometrial problems (with p-values of 0.033 and 0.024, respectively). No significant changes were detected in categories including polyp, adenomyosis, leiomyoma, malignancy, and iatrogenic causes (p>0.05). CONCLUSIONS: In the relationship between COVID-19, ovulatory dysfunction, and endometrial issues, several factors should be considered. These include direct inflammation of the ovarian and endometrial tissues, potential defects in endometrial repair mechanisms secondary to inflammation, changes in the hypothalamic-pituitary-ovarian axis, immunological effects of vaccination, systemic inflammatory responses affecting the ovary and endometrium, changes in inflammatory and immune mediators, and immune cell activation. Additionally, increased production of vasodilatory substances such as prostaglandin E2 and prostacyclin, decreased production of local vasoconstrictors like prostaglandin F2α and endothelin-1, as well as increased plasminogen activator activity leading to enhanced thrombolysis and disruptions in endometrial hemostatic mechanisms.
- 19 December 2024
- Published by Mebas Medikal Basin Yayin Ltd. Sti in Gynecology Obstetrics & Reproductive Medicine
- p. 1-6
Open AccessThe Effects of the COVID-19 Pandemic on Abnormal Uterine Bleeding According to the PALM-COEIN Classification
OBJECTIVE: To investigate the impact of the COVID-19 pandemic on abnormal uterine bleeding (AUB) according to the PALM-COEIN classification. STUDY DESIGN: Patients who underwent surgical intervention due to AUB were categorized according to the PALM-COEIN classification, and the pandemic period was compared with the pre-pandemic period. RESULTS: During the COVID-19 pandemic, an increase in abnormal uterine bleeding (AUB) was observed. This was statistically shown to be due to ovulatory dysfunction and endometrial problems (with p-values of 0.033 and 0.024, respectively). No significant changes were detected in categories including polyp, adenomyosis, leiomyoma, malignancy, and iatrogenic causes (p>0.05). CONCLUSIONS: In the relationship between COVID-19, ovulatory dysfunction, and endometrial issues, several factors should be considered. These include direct inflammation of the ovarian and endometrial tissues, potential defects in endometrial repair mechanisms secondary to inflammation, changes in the hypothalamic-pituitary-ovarian axis, immunological effects of vaccination, systemic inflammatory responses affecting the ovary and endometrium, changes in inflammatory and immune mediators, and immune cell activation. Additionally, increased production of vasodilatory substances such as prostaglandin E2 and prostacyclin, decreased production of local vasoconstrictors like prostaglandin F2α and endothelin-1, as well as increased plasminogen activator activity leading to enhanced thrombolysis and disruptions in endometrial hemostatic mechanisms.
- Open Access
- 29 August 2024
- Published by Galenos Yayinevi in Journal of the Turkish-German Gynecological Association
- Vol. 25 (3) , 144-151
Single-center experience of laparoscopic hysterectomy: analysis of one thousand five hundred and fifteen patients
Single-center experience of laparoscopic hysterectomy: analysis of one thousand five hundred and fifteen patients - Journal of the Turkish-German Gynecological Association
- 29 August 2024
- Published by Galenos Yayinevi in Journal of the Turkish-German Gynecological Association
- Vol. 25 (3) , 144-151
Open AccessSingle-center experience of laparoscopic hysterectomy: analysis of one thousand five hundred and fifteen patients
Single-center experience of laparoscopic hysterectomy: analysis of one thousand five hundred and fifteen patients - Journal of the Turkish-German Gynecological Association
- 25 July 2023
- Published by Springer Nature in Indian Journal of Surgery
- Vol. 86 (2) , 355-360
Evaluatıon of Four Cases of Fertility-Sparing Surgery in Cervical Sarcoma and Review of the Literature
- 25 July 2023
- Published by Springer Nature in Indian Journal of Surgery
- Vol. 86 (2) , 355-360
Evaluatıon of Four Cases of Fertility-Sparing Surgery in Cervical Sarcoma and Review of the Literature
- 30 November 2022
- Published by Medknow in Indian Journal of Cancer
- Vol. 60 (3) , 366-372
Safety of laparoscopic surgery in the management of endometrioid endometrial cancer
Background: Laparoscopic surgery has increasingly been preferred in recent years. However, data regarding the safety of laparoscopy in endometrial cancer are not sufficient. The aim of this study was to compare perioperative and oncologic outcomes of laparoscopic and laparotomic staging surgery in patients with endometrioid endometrial cancer and to evaluate the safety and efficacy of laparoscopic surgery in this population. Methods: Data of 278 patients, who underwent surgical staging for endometrioid endometrial cancer at the gynecologic oncology department of a university hospital between 2012 and 2019, were analyzed retrospectively. Demographic, histopathologic, perioperative, and oncologic characteristics were compared between laparoscopy and laparotomy groups. A subgroup of patients with a body mass index (BMI) >30 was further evaluated. Results: Demographic and histopathologic characteristics were similar between the two groups, while laparoscopic surgery was seen to be significantly superior in terms of perioperative outcomes. The number of removed and metastatic lymph nodes was significantly higher in the laparotomy group; however, this difference did not affect the oncologic outcomes, including recurrence and survival rates, and the two groups had similar results in this aspect. The outcomes of the subgroup with BMI >30 were also in accordance with the whole population. Intraoperative complications in laparoscopy were managed successfully. Conclusions: Laparoscopic surgery appears to be advantageous over laparotomy, and depending on the surgical experience, it may be performed safely for surgical staging of endometrioid endometrial cancer.
- 30 November 2022
- Published by Medknow in Indian Journal of Cancer
- Vol. 60 (3) , 366-372
Safety of laparoscopic surgery in the management of endometrioid endometrial cancer
Background: Laparoscopic surgery has increasingly been preferred in recent years. However, data regarding the safety of laparoscopy in endometrial cancer are not sufficient. The aim of this study was to compare perioperative and oncologic outcomes of laparoscopic and laparotomic staging surgery in patients with endometrioid endometrial cancer and to evaluate the safety and efficacy of laparoscopic surgery in this population. Methods: Data of 278 patients, who underwent surgical staging for endometrioid endometrial cancer at the gynecologic oncology department of a university hospital between 2012 and 2019, were analyzed retrospectively. Demographic, histopathologic, perioperative, and oncologic characteristics were compared between laparoscopy and laparotomy groups. A subgroup of patients with a body mass index (BMI) >30 was further evaluated. Results: Demographic and histopathologic characteristics were similar between the two groups, while laparoscopic surgery was seen to be significantly superior in terms of perioperative outcomes. The number of removed and metastatic lymph nodes was significantly higher in the laparotomy group; however, this difference did not affect the oncologic outcomes, including recurrence and survival rates, and the two groups had similar results in this aspect. The outcomes of the subgroup with BMI >30 were also in accordance with the whole population. Intraoperative complications in laparoscopy were managed successfully. Conclusions: Laparoscopic surgery appears to be advantageous over laparotomy, and depending on the surgical experience, it may be performed safely for surgical staging of endometrioid endometrial cancer.
- 29 October 2022
- Published by Springer Nature in Indian Journal of Gynecologic Oncology
- Vol. 20 (4) , 1-8
Importance of Laparoscopy in Predicting Complete Cytoreduction at Advanced Stage Ovarian Cancer
- 29 October 2022
- Published by Springer Nature in Indian Journal of Gynecologic Oncology
- Vol. 20 (4) , 1-8
Importance of Laparoscopy in Predicting Complete Cytoreduction at Advanced Stage Ovarian Cancer
- Open Access
- 9 July 2022
- Published by Mebas Medikal Basin Yayin Ltd. Sti in Gynecology Obstetrics & Reproductive Medicine
- p. 1-5
Leuprolide Acetate Treatment for Ovarian Cysts in Breast Cancer Patients Under Tamoxifen Therapy
OBJECTIVE: The aim of this study is to evaluate the outcomes of gonadotropin-releasing hormone agonist treatment for ovarian cysts, which are developed during tamoxifen use due to breast cancer. STUDY DESIGN: This was a retrospective cohort study including the patients who were under tamoxifen treatment due to stage I-III breast cancer and who were administered leuprolide acetate for ovarian cysts with low malignancy risk between 2012-2020. RESULTS: Leuprolide acetate was administered to a total of 16 patients with ovarian cysts. The median age was 39.5 (33-52), the median size of the ovarian cyst was 42.5 (39-79) mm, and the median duration of tamoxifen use was 22 (7-36) months. Leuprolide acetate was administered at doses of 3.75 mg for 1 month at 10 (62.5%) patients, 7.5 mg in two months at 3 (18.75%) patients, and 11.25 mg in three months at 3 (18.75%) patients. Ovarian cysts were regressed after treatment at 13 patients, while 3 patients underwent surgery. CONCLUSION: Leuprolide acetate can be used as an option in the treatment of ovarian cysts that develop in breast cancer patients under tamoxifen therapy. Keywords: Breast neoplasms, Gonadotropin-releasing hormone, Ovary, Ovarian cyst, Tamoxifen
- 9 July 2022
- Published by Mebas Medikal Basin Yayin Ltd. Sti in Gynecology Obstetrics & Reproductive Medicine
- p. 1-5
Open AccessLeuprolide Acetate Treatment for Ovarian Cysts in Breast Cancer Patients Under Tamoxifen Therapy
OBJECTIVE: The aim of this study is to evaluate the outcomes of gonadotropin-releasing hormone agonist treatment for ovarian cysts, which are developed during tamoxifen use due to breast cancer. STUDY DESIGN: This was a retrospective cohort study including the patients who were under tamoxifen treatment due to stage I-III breast cancer and who were administered leuprolide acetate for ovarian cysts with low malignancy risk between 2012-2020. RESULTS: Leuprolide acetate was administered to a total of 16 patients with ovarian cysts. The median age was 39.5 (33-52), the median size of the ovarian cyst was 42.5 (39-79) mm, and the median duration of tamoxifen use was 22 (7-36) months. Leuprolide acetate was administered at doses of 3.75 mg for 1 month at 10 (62.5%) patients, 7.5 mg in two months at 3 (18.75%) patients, and 11.25 mg in three months at 3 (18.75%) patients. Ovarian cysts were regressed after treatment at 13 patients, while 3 patients underwent surgery. CONCLUSION: Leuprolide acetate can be used as an option in the treatment of ovarian cysts that develop in breast cancer patients under tamoxifen therapy. Keywords: Breast neoplasms, Gonadotropin-releasing hormone, Ovary, Ovarian cyst, Tamoxifen
- 6 April 2022
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 48 (7) , 1876-1887
Uterine papillary serous and clear cell carcinomas: Comparison of characteristics and clinical outcomes
Introduction To assess the rate of disease control and survival after adjuvant treatment in patients with uterine papillary serous (PSC) and clear cell carcinoma (CCC) and compare the results between these two subtypes. Methods The medical charts of 199 patients with de novo uterine PSC or CCC who underwent radiotherapy (RT) following surgery between 2001 and 2019 in three radiation oncology departments were retrospectively evaluated. Adjuvant treatment was decided by a multidisciplinary tumor board. All patients were planned to undergo adjuvant 4-6 cycles of chemotherapy with external beam RT (EBRT) and/or vaginal brachytherapy (VBT). Results Median age was 63 years for all, 64 years for PSC, and 59 years for CCC, respectively. Complete surgical staging was applied in 98% of patients. Histopathologic subtype was PSC in 142 (71%) and pure CCC in 57 (29%) patients, respectively. FIGO stage was I in 107 (54%), II in 35 (18%), and III in 57 (28%) patients, respectively. Lympho-vascular space invasion and positive peritoneal cytology (PPC) were present in 42% and 10% of patients, respectively. All patients but 23 (12%) underwent adjuvant chemotherapy. Median follow-up was 49.5 months for all patients, 43.9 months for patients with PSC, and 90.4 months for patients with CCC, respectively. During follow-up, 20 (10%) patients developed pelvic recurrence (PR) and 37 (19%) developed distant metastasis (DM). PSC subtype increased the PR and DM rates, although the latter not statistically significant. The 5-year overall survival and disease-free survival rate was 73% and 69% for all patients, 71% and 66% for patients with PSC, and 77% and 75% for patients with CCC, respectively. The difference was more prominent in patients with stage >= IB disease. In multivariate analysis, advanced age and PPC significantly decreased all survival rates. Conclusion PSC has a worse prognosis than CCC with regard to pelvic and distant recurrence with a trend for decreased survival rates. Therefore, a more aggressive therapy is needed for patients with uterine PSC, particularly in patients with stage >= IB disease.
- 6 April 2022
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 48 (7) , 1876-1887
Uterine papillary serous and clear cell carcinomas: Comparison of characteristics and clinical outcomes
Introduction To assess the rate of disease control and survival after adjuvant treatment in patients with uterine papillary serous (PSC) and clear cell carcinoma (CCC) and compare the results between these two subtypes. Methods The medical charts of 199 patients with de novo uterine PSC or CCC who underwent radiotherapy (RT) following surgery between 2001 and 2019 in three radiation oncology departments were retrospectively evaluated. Adjuvant treatment was decided by a multidisciplinary tumor board. All patients were planned to undergo adjuvant 4-6 cycles of chemotherapy with external beam RT (EBRT) and/or vaginal brachytherapy (VBT). Results Median age was 63 years for all, 64 years for PSC, and 59 years for CCC, respectively. Complete surgical staging was applied in 98% of patients. Histopathologic subtype was PSC in 142 (71%) and pure CCC in 57 (29%) patients, respectively. FIGO stage was I in 107 (54%), II in 35 (18%), and III in 57 (28%) patients, respectively. Lympho-vascular space invasion and positive peritoneal cytology (PPC) were present in 42% and 10% of patients, respectively. All patients but 23 (12%) underwent adjuvant chemotherapy. Median follow-up was 49.5 months for all patients, 43.9 months for patients with PSC, and 90.4 months for patients with CCC, respectively. During follow-up, 20 (10%) patients developed pelvic recurrence (PR) and 37 (19%) developed distant metastasis (DM). PSC subtype increased the PR and DM rates, although the latter not statistically significant. The 5-year overall survival and disease-free survival rate was 73% and 69% for all patients, 71% and 66% for patients with PSC, and 77% and 75% for patients with CCC, respectively. The difference was more prominent in patients with stage >= IB disease. In multivariate analysis, advanced age and PPC significantly decreased all survival rates. Conclusion PSC has a worse prognosis than CCC with regard to pelvic and distant recurrence with a trend for decreased survival rates. Therefore, a more aggressive therapy is needed for patients with uterine PSC, particularly in patients with stage >= IB disease.